SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/15 Bionik Laboratories Corp. 10-K 12/31/14 48:1.6M Walker Jody M/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 273K 2: EX-14.1 Code of Ethics -- exhibit141 HTML 60K 3: EX-21 Exhibit 21.1 HTML 15K 4: EX-31 Certification -- §302 - SOA'02 -- exhibit31 HTML 24K 5: EX-32 Certification -- §906 - SOA'02 -- exhibit32 HTML 21K 31: R1 Document and Entity Information HTML 47K 24: R2 Bionik Laboratories Corp. (f/k/a Drywave HTML 63K Technologies, Inc.) Consolidated Balance Sheets 29: R3 Bionik Laboratories Corp. (f/k/a Drywave HTML 42K Technologies, Inc.) - Consolidated Balance Sheets (Parantheticals)(Usd $) 33: R4 Bionik Laboratories Corp. (f/k/a Drywave HTML 50K Technologies, Inc.) - Consolidated Statements of Operations 44: R5 Bionik Laboratories Corp. (f/k/a Drywave HTML 37K Technologies, Inc.) - Consolidated Statement of Changes in Stockholders' Equity (Deficit) For the Years Ended December 31, 2014 and 2013 25: R6 Bionik Laboratories Corp. (f/k/a Drywave HTML 54K Technologies, Inc.) - Consolidated Statements of Cash Flows 28: R7 Note 1 Nature of Operations HTML 23K 21: R8 Note 2 Summary of Significant Accounting Policies HTML 33K 15: R9 Note 3 Going Concern HTML 22K 45: R10 Note 4 Related Party Transactions HTML 25K 35: R11 Note 5 Stockholders' Deficit HTML 29K 34: R12 Note 6 Income Taxes HTML 22K 39: R13 Note 7 Commitments and Contingencies HTML 22K 40: R14 Note 8 Subsequent Events HTML 36K 38: R15 Note 2 Summary of Significant Accounting Policies: HTML 20K Basis of Presentation (Policies) 41: R16 Note 2 Summary of Significant Accounting Policies: HTML 23K Principles of Consolidation (Policies) 30: R17 Note 2 Summary of Significant Accounting Policies: HTML 24K Development Stage Entity (Policies) 32: R18 Note 2 Summary of Significant Accounting Policies: HTML 20K Use of Estimates (Policies) 37: R19 Note 2 Summary of Significant Accounting Policies: HTML 22K Cash and Cash Equivalents (Policies) 48: R20 Note 2 Summary of Significant Accounting Policies: HTML 21K Property and Equipment (Policies) 42: R21 Note 2 Summary of Significant Accounting Policies: HTML 19K Due To Related Party (Policies) 26: R22 Note 2 Summary of Significant Accounting Policies: HTML 20K Financial Instruments (Policies) 36: R23 Note 2 Summary of Significant Accounting Policies: HTML 22K Revenue Recognition (Policies) 27: R24 Note 2 Summary of Significant Accounting Policies: HTML 20K Advertising Expenses (Policies) 14: R25 Note 2 Summary of Significant Accounting Policies: HTML 24K Income Taxes (Policies) 43: R26 Note 2 Summary of Significant Accounting Policies: HTML 21K Stock Based Compensation (Policies) 46: R27 Note 2 Summary of Significant Accounting Policies: HTML 23K Earnings (loss) Per Share (Policies) 18: R28 Note 2 Summary of Significant Accounting Policies: HTML 19K Reclassification (Policies) 17: R29 Note 2 Summary of Significant Accounting Policies: HTML 19K Recent Accounting Pronouncements (Policies) 19: R30 Note 3 Going Concern (Details) HTML 30K 20: R31 Note 4 Related Party Transactions (Details) HTML 24K 22: R32 Note 6 Income Taxes (Details) HTML 27K 13: R33 Note 8 Subsequent Events (Details) HTML 43K 47: XML IDEA XML File -- Filing Summary XML 69K 12: EXCEL IDEA Workbook of Financial Reports XLSX 51K 16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 113K 6: EX-101.INS XBRL Instance -- dwtp-20141231 XML 149K 8: EX-101.CAL XBRL Calculations -- dwtp-20141231_cal XML 35K 9: EX-101.DEF XBRL Definitions -- dwtp-20141231_def XML 60K 10: EX-101.LAB XBRL Labels -- dwtp-20141231_lab XML 240K 11: EX-101.PRE XBRL Presentations -- dwtp-20141231_pre XML 195K 7: EX-101.SCH XBRL Schema -- dwtp-20141231 XSD 76K 23: ZIP XBRL Zipped Folder -- 0001014897-15-000132-xbrl Zip 32K
Exhibit 21.1 |
EXHIBIT 21.1
Bionik Acquisition Inc., a company existing under the laws of Canada and a wholly owned subsidiary.
Bionik Laboratories Inc., a company existing under the laws of Canada. Bionik Acquisition Inc. owns 100 Class 1 common shares of Bionik Laboratories Inc., representing 100% of the outstanding Class 1 common shares of Bionik Laboratories Inc.
1
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/21/23 Bionik Laboratories Corp. 10-K 3/31/23 78:8.6M Toppan Merrill/FA2 6/09/22 Bionik Laboratories Corp. 10-K 3/31/22 68:7.9M Toppan Merrill/FA2 6/24/21 Bionik Laboratories Corp. 10-K 3/31/21 71:6.3M Toppan Merrill/FA |